JP2004520031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520031A5 JP2004520031A5 JP2002555832A JP2002555832A JP2004520031A5 JP 2004520031 A5 JP2004520031 A5 JP 2004520031A5 JP 2002555832 A JP2002555832 A JP 2002555832A JP 2002555832 A JP2002555832 A JP 2002555832A JP 2004520031 A5 JP2004520031 A5 JP 2004520031A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- fusion protein
- acid construct
- pharmaceutically active
- mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 18
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 16
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 230000006337 proteolytic cleavage Effects 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 2
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims 2
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102100030417 Matrilysin Human genes 0.000 claims 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 102100030411 Neutrophil collagenase Human genes 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 102100030416 Stromelysin-1 Human genes 0.000 claims 2
- 102100028848 Stromelysin-2 Human genes 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000002516 radical scavenger Substances 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 claims 1
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000010382 chemical cross-linking Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/756,283 US6942853B2 (en) | 2001-01-09 | 2001-01-09 | Latent fusion protein |
| GBGB0100551.1A GB0100551D0 (en) | 2001-01-09 | 2001-01-09 | Protein |
| PCT/GB2002/000068 WO2002055098A2 (en) | 2001-01-09 | 2002-01-09 | Latency associated peptide for providing latency to pharmaceutically active proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004520031A JP2004520031A (ja) | 2004-07-08 |
| JP2004520031A5 true JP2004520031A5 (https=) | 2005-12-22 |
| JP4201253B2 JP4201253B2 (ja) | 2008-12-24 |
Family
ID=26245544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555832A Expired - Fee Related JP4201253B2 (ja) | 2001-01-09 | 2002-01-09 | 薬学的活性物質に潜在性を提供する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6942853B2 (https=) |
| EP (1) | EP1349944B1 (https=) |
| JP (1) | JP4201253B2 (https=) |
| AT (1) | ATE293169T1 (https=) |
| AU (1) | AU2002219345B2 (https=) |
| DE (1) | DE60203692T2 (https=) |
| DK (1) | DK1349944T3 (https=) |
| ES (1) | ES2240740T3 (https=) |
| GB (1) | GB0100551D0 (https=) |
| WO (1) | WO2002055098A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| CN101044154A (zh) * | 2002-02-14 | 2007-09-26 | 威廉·J·鲁特 | 治疗宿主中切割的嵌合分子 |
| WO2007044321A2 (en) * | 2005-10-04 | 2007-04-19 | Greenville Hospital System | Latent procytotoxins and uses thereof |
| DE102006009324A1 (de) | 2006-03-01 | 2007-09-06 | Dr.Ing.H.C. F. Porsche Ag | Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts |
| EP2091568A2 (en) * | 2006-10-31 | 2009-08-26 | East Carolina University | Fusion proteins comprising a anti-inflammatory cytokine and an antigen for treatment of immune disorders |
| GB0724556D0 (en) * | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| FR2932190A1 (fr) * | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease |
| CA2757287C (en) | 2009-03-31 | 2019-09-10 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
| GB0911365D0 (en) | 2009-06-30 | 2009-08-12 | Bioceramic Therapeutics Ltd | Multicomponent glasses for use as coatings and in personal care products |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| EP2878308B1 (en) * | 2013-12-02 | 2018-10-31 | Thomas Harder | Agents and methods for the suppression of T cell activation |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| ES2780274A1 (es) | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| WO2021207669A1 (en) * | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| CA2003886A1 (en) | 1988-12-16 | 1990-06-16 | Anthony F. Purchio | Cloning and expression of simian transforming growth factor-beta 1 |
| EP0502036B1 (en) | 1989-11-22 | 1995-12-20 | Genentech, Inc. | Latency associated peptide and uses therefor |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| WO1994026892A1 (en) | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-11 compositions |
| CA2151547C (en) | 1994-06-10 | 2010-10-12 | Elliott A. Gruskin | Recombinant chimeric proteins and methods of use thereof |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| WO1997012048A1 (en) * | 1995-09-27 | 1997-04-03 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| AU7023798A (en) * | 1997-04-30 | 1998-11-24 | De Novo Enzyme Corporation | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| GB2324960A (en) | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| CA2345024C (en) | 1998-10-07 | 2009-05-19 | Stryker Corporation | Modified tgf-.beta. superfamily proteins |
| CA2421582A1 (en) * | 2000-09-11 | 2002-03-21 | The Trustees Of Columbia University In The City Of New York | Combinatorial fluorescence energy transfer tags and uses thereof |
-
2001
- 2001-01-09 US US09/756,283 patent/US6942853B2/en not_active Expired - Lifetime
- 2001-01-09 GB GBGB0100551.1A patent/GB0100551D0/en not_active Ceased
-
2002
- 2002-01-09 ES ES02729440T patent/ES2240740T3/es not_active Expired - Lifetime
- 2002-01-09 WO PCT/GB2002/000068 patent/WO2002055098A2/en not_active Ceased
- 2002-01-09 EP EP02729440A patent/EP1349944B1/en not_active Expired - Lifetime
- 2002-01-09 DE DE60203692T patent/DE60203692T2/de not_active Expired - Lifetime
- 2002-01-09 AU AU2002219345A patent/AU2002219345B2/en not_active Ceased
- 2002-01-09 JP JP2002555832A patent/JP4201253B2/ja not_active Expired - Fee Related
- 2002-01-09 AT AT02729440T patent/ATE293169T1/de not_active IP Right Cessation
- 2002-01-09 DK DK02729440T patent/DK1349944T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520031A5 (https=) | ||
| Le et al. | The dual personalities of matrix metalloproteinases in inflammation | |
| Pérez-García et al. | Profile of matrix-remodeling proteinases in osteoarthritis: impact of fibronectin | |
| Van Lint et al. | Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation | |
| Opdenakker et al. | Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer | |
| Murphy et al. | What are the roles of metalloproteinases in cartilage and bone damage? | |
| Cawston et al. | Proteinases involved in matrix turnover during cartilage and bone breakdown | |
| Murphy | Matrix metalloproteinases and their inhibitors | |
| Birkedal‐Hansen | Role of cytokines and inflammatory mediators in tissue destruction | |
| Uchida et al. | Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells | |
| Cudic et al. | Extracellular proteases as targets for drug development | |
| Song et al. | Matrix metalloproteinase dependent and independent collagen degradation | |
| Fibbe et al. | The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization | |
| FI3794024T3 (fi) | Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä | |
| Firestein | Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis | |
| Takagi et al. | Matrix Metalloprotemases and Tissue Inhibitors of Metalloproteinases in Loose Artificial Hip Joints | |
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| Cawston et al. | Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease | |
| ES2203088T3 (es) | Nuevos inhibidores y reguladores negativos de metaloproteinasas de matriz. | |
| Demers et al. | New roles for matrix metalloproteinases in metastasis | |
| NAKAGAWA et al. | Changes in the levels of rat interleukin 8/CINC and gelatinase in the exudate of carrageenin-induced inflammation in rats | |
| Yoshimura et al. | Transcriptional and posttranscriptional modulation of human neutrophil elastase gene expression | |
| US20130149295A1 (en) | Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease | |
| Cox et al. | Cytokine substrates: MMP regulation of inflammatory signaling molecules | |
| CN106496329B (zh) | 一种含有胶原蛋白结合结构域的融合蛋白 |